Here in essence is the typical timeline for Biotech that needs to go all the way from preclinical development into Phase I, Phase II and Phase II trials and then approval.
Bisantrene has over 40 II and III clinical trials - all data that helps RAC accelerate their planned Phase II trials, with possibility of Bisantrene being accelerated to approval for AML under the 505(b)(2) pathway.
This is from a CUV presentation. Clinical studies first started in 2006.
https://www.asx.com.au/asxpdf/20200520/pdf/44hz58ck3dn2gd.pdf
Here in essence is the typical timeline for Biotech that needs...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |